A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.
Inclusion Criteria:
Exclusion Criteria:
San Francisco, California 94115, United States
Kansas City, Kansas 66160, United States
Montreal, Quebec H3A 2B4, Canada
Narita, Chiba 286-8520, Japan
Kita-gun, Japan
Poznan, Greater Poland Voivodeship 61-853, Poland
Krakow, Lesser Poland Voivodeship 31-202, Poland
Lublin, Lublin Voivodeship 20-093, Poland
Katowice, Silesian Voivodeship 40-123, Poland
Katowice, Silesian Voivodeship 40-650, Poland